June 9, 2014

Merck and Idenix Pharmaceuticals on Monday announced that the companies have entered into a definitive agreement under which Merck will acquire Idenix for $24.50 per share in cash.

June 9, 2010

Idenix Pharmaceuticals has started a proof-of-concept study of an investigational drug for hepatitis C currently...